

Carlo Rinaldi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6370980/publications.pdf>

Version: 2024-02-01

39
papers

1,750
citations

331259

21
h-index

301761

39
g-index

41
all docs

41
docs citations

41
times ranked

3086
citing authors

#	ARTICLE	IF	CITATIONS
1	Antisense oligonucleotides: the next frontier for treatment of neurological disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 9-21.	4.9	515
2	Cowchock Syndrome Is Associated with a Mutation in Apoptosis-Inducing Factor. <i>American Journal of Human Genetics</i> , 2012, 91, 1095-1102.	2.6	134
3	Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing/remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 450-454.	1.4	79
4	Hereditary Spastic Paraplegia Type 43 (SPG43) is Caused by Mutation in <i>C19orf12</i> . <i>Human Mutation</i> , 2013, 34, 1357-1360.	1.1	79
5	Mutation in <i>CPT1C</i> Associated With Pure Autosomal Dominant Spastic Paraplegia. <i>JAMA Neurology</i> , 2015, 72, 561.	4.5	64
6	MicroRNA-298 reduces levels of human amyloid- β^2 precursor protein (APP), β^2 -site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. <i>Molecular Psychiatry</i> , 2021, 26, 5636-5657.	4.1	61
7	Insulinlike Growth Factor (IGF)-1 Administration Ameliorates Disease Manifestations in a Mouse Model of Spinal and Bulbar Muscular Atrophy. <i>Molecular Medicine</i> , 2012, 18, 1261-1268.	1.9	56
8	A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. <i>Human Molecular Genetics</i> , 2016, 25, 1979-1989.	1.4	55
9	Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients. <i>Neurobiology of Disease</i> , 2014, 70, 12-20.	2.1	49
10	Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 808-812.	0.9	48
11	A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. <i>Journal of Neurology</i> , 2012, 259, 132-138.	1.8	47
12	Predictors of Survival in a Huntington's Disease Population from Southern Italy. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 48-51.	0.3	41
13	Spinal and bulbar muscular atrophy: pathogenesis and clinical management. <i>Oral Diseases</i> , 2014, 20, 6-9.	1.5	41
14	Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. <i>Neurology</i> , 2019, 92, e1205-e1211.	1.5	41
15	Two novel CYP7B1 mutations in Italian families with SPG5: a clinical and genetic study. <i>Journal of Neurology</i> , 2009, 256, 1252-1257.	1.8	39
16	Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat. <i>Neuromuscular Disorders</i> , 2014, 24, 978-981.	0.3	37
17	Benign hereditary chorea: Clinical and neuroimaging features in an Italian family. <i>Movement Disorders</i> , 2010, 25, 1491-1495.	2.2	32
18	The Role of the Protein Quality Control System in SBMA. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 348-364.	1.1	32

#	ARTICLE	IF	CITATIONS
19	The R495W mutation in SPG3A causes spastic paraplegia associated with axonal neuropathy. <i>Journal of Neurology</i> , 2005, 252, 901-903.	1.8	31
20	MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy. <i>Molecular Therapy</i> , 2016, 24, 937-945.	3.7	29
21	The Multiple Faces of Spinocerebellar Ataxia type 2. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 687-695.	1.7	24
22	A candidate gene for autoimmune myasthenia gravis. <i>Neurology</i> , 2012, 79, 342-347.	1.5	21
23	Polyglutamine-Expanded Androgen Receptor Alteration of Skeletal Muscle Homeostasis and Myonuclear Aggregation Are Affected by Sex, Age and Muscle Metabolism. <i>Cells</i> , 2020, 9, 325.	1.8	21
24	Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity. <i>Science Advances</i> , 2021, 7, .	4.7	20
25	Insulin Sensitivity and Early-Phase Insulin Secretion in Normoglycemic Huntington's Disease Patients. <i>Journal of Huntington's Disease</i> , 2013, 2, 501-507.	0.9	18
26	From gene to therapy in spinal and bulbar muscular atrophy: Are we there yet?. <i>Molecular and Cellular Endocrinology</i> , 2018, 465, 113-121.	1.6	18
27	Ataxia with oculomotor apraxia type 2 fibroblasts exhibit increased susceptibility to oxidative DNA damage. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1627-1631.	0.8	15
28	Suppression of myoclonus in SCA2 by piracetam. <i>Movement Disorders</i> , 2006, 21, 116-118.	2.2	14
29	Course and outcome of a voltage-gated potassium channel antibody negative Morvan's syndrome. <i>Neurological Sciences</i> , 2009, 30, 237-239.	0.9	14
30	Muscle Matters in Kennedy's Disease. <i>Neuron</i> , 2014, 82, 251-253.	3.8	13
31	Plasma pNfH levels differentiate SBMA from ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 215-217.	0.9	11
32	Growth hormone response to arginine test differentiates between two subgroups of Huntington's disease patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 543-547.	0.9	10
33	Targeted Molecular Therapies for SBMA. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 335-342.	1.1	10
34	Variants in <i>ATP6VOA1</i> cause progressive myoclonus epilepsy and developmental and epileptic encephalopathy. <i>Brain Communications</i> , 2021, 3, fcb245.	1.5	10
35	Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	7
36	AR cooperates with SMAD4 to maintain skeletal muscle homeostasis. <i>Acta Neuropathologica</i> , 2022, 143, 713-731.	3.9	6

#	ARTICLE	IF	CITATIONS
37	Proteostasis and Diseases of the Motor Unit. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 164.	1.4	4
38	Targeting the 5' untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 731-742.	2.3	3
39	Dystrophin involvement in peripheral circadian SRF signalling. <i>Life Science Alliance</i> , 2021, 4, e202101014.	1.3	1